• +1-646-491-9876
    • +91-20-67278686

    Search

    Pressure Ulcers - Pipeline Review, H1 2017

    Pressure Ulcers - Pipeline Review, H1 2017

    • Report Code ID: RW0001689448
    • Category Healthcare
    • No. of Pages 37
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H1 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

    Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 5 respectively.

    Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).
    - The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Pressure Ulcers - Overview
    Pressure Ulcers - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Pressure Ulcers - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Pressure Ulcers - Companies Involved in Therapeutics Development
    EyeGene Inc
    Izun Pharmaceuticals Corp
    MediWound Ltd
    NovaLead Pharma Pvt Ltd
    RegeneRx Biopharmaceuticals Inc
    RMB-Research GmbH
    Pressure Ulcers - Drug Profiles
    AG-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EG-Decorin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EscharEx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IZN-6D4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NLP-328 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RGN-137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Statmicoll - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Pressure Ulcers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Pressure Ulcers - Dormant Projects
    Pressure Ulcers - Discontinued Products
    Pressure Ulcers - Product Development Milestones
    Featured News & Press Releases
    Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016
    Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment
    Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results
    Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137
    Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial
    Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Pressure Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pressure Ulcers - Pipeline by EyeGene Inc, H1 2017
    Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2017
    Pressure Ulcers - Pipeline by MediWound Ltd, H1 2017
    Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
    Pressure Ulcers - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
    Pressure Ulcers - Pipeline by RMB-Research GmbH, H1 2017
    Pressure Ulcers - Dormant Projects, H1 2017
    Pressure Ulcers - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Pressure Ulcers, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    EyeGene Inc
    Izun Pharmaceuticals Corp
    MediWound Ltd
    NovaLead Pharma Pvt Ltd
    RegeneRx Biopharmaceuticals Inc
    RMB-Research GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//pressure-ulcers-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//pressure-ulcers-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//pressure-ulcers-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments